Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluating Lipid-Lowering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization.

Annals of neurology - 1 Nov 2020

Williams Dylan M, Bandres-Ciga Sara, Heilbron Karl, Hinds David, Noyce Alastair J

Abstract excerpt

Long-term exposure to lipid-lowering drugs might affect Parkinson's disease (PD) risk. We conducted Mendelian randomization analyses where genetic variants indexed expected effects of modulating lipid-lowering drug targets on PD. Statin exposure was not predicted to increase PD risk, although results were not precise enough to support benefits for prevention clearly (odds ratio [OR] = 0.83; 95% confidence...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Apolipoprotein A-V

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Apolipoproteins B

Share to Cholesterol, LDL

Share to Cholesterol, VLDL

Share to Hypolipidemic Agents

Share to Mendelian Randomization Analysis

Share to Triglycerides

Source

Open in PubMed Open full text

Identifiers

PMID: 32841444
DOI: 10.1002/ana.25880
PMCID: PMC7693098

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluating Lipid-Lowering Drug Targets for Parkinson's Disease Prevention with Mendelian Randomization.PMID 32841444Read ↗

Evaluating lipid-lowering drug targets for Parkinson disease prevention with Mendelian randomizationSemantic proximity Read ↗

Genetic Associations of Lipid-Lowering Drugs and Parkinson’s Disease: A Mendelian Randomization StudySemantic proximity Read ↗

The Parkinson's Disease Mendelian Randomization Research Portal.Semantic proximity Read ↗

Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome.Semantic proximity Read ↗

Finding drug targeting mechanisms with genetic evidence for Parkinson’s diseaseSemantic proximity Read ↗

Lipid lowering and Alzheimer disease risk: A mendelian randomization study.Semantic proximity Read ↗

Discovery and Exploration of Lipid-Modifying Drug Targets for ALS by Mendelian Randomization.Semantic proximity Read ↗

Genetic insights of lipid metabolism and lipid-lowering drugs with Lewy body dementia risk: Evidence from Mendelian randomization.Semantic proximity Read ↗

Systematic genome-wide Mendelian randomization reveals the causal links between miRNAs and Parkinson’s diseaseSemantic proximity Read ↗

<scp>M</scp> endelian <scp>R</scp> andomization — the <scp>K</scp> ey to <scp>U</scp> nderstanding <scp>A</scp> spects of <scp>P</scp> arkinson's <scp>D</scp> isease <scp>C</scp> ausation?Semantic proximity Read ↗

Perspectives of People At-Risk on Parkinson's Prevention Research.Semantic proximity Read ↗

Associations between polyunsaturated fatty acid concentrations and Parkinson’s disease: A two-sample Mendelian randomization studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.